PSNLPersonalis, Inc.
Is the business good?
The checks split: margins widening, but 3 of 9 health tests passed.
Weak, deteriorating fundamentals. Nine pass/fail tests of year-over-year health from the filings.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is PSNL?
Personalis, Inc. keeps −164% of every revenue dollar as operating profit, against 3.6% for the median Diagnostics & Research name.
Operating margin · Diagnostics & Research median 3.6% · 12 months to Q2 2026
- Share count, year on year
- +19%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 81%
R&D as % of revenue
- Gross margin
- 13%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −54% |
| FY2021 | −76% |
| FY2022 | −178% |
| FY2023 | −150% |
| FY2024 | −81% |
| FY2025 | −126% |
Details›
- Gross margin12 months to Q2 2026
- 13%
- Operating margin12 months to Q2 2026
- −164%
- Net margin12 months to Q2 2026
- −154%
- Free cash flow margin
- −145%
- R&D as % of revenue
- 81%
- Revenue, trailing twelve months
- $70M
- Free cash flow, trailing twelve months
- −$101M
- Net income, trailing twelve months
- −$107M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Diagnostics & Research
Ranks #21 of 21 by RyuScore